Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (341-350 of 491) with videos related to

Pageof 50
Sort By:
International Journal of Molecular Sciences|February 27, 2026
Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in ChondrosarcomaAgnieszka E Zając, Piotr Rutkowski, Anna Szumera-Ciećkiewicz, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 2020
Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohortNikki S IJzerman, Mahmoud Mohammadi, Dimitri Tzanis, et al.
Annals of Surgery|January 5, 2016
Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working GroupAlessandro Gronchi, Dirk C Strauss, Rosalba Miceli, et al.
Immunotherapy|December 23, 2020
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in PolandBożena Cybulska-Stopa, Renata Pacholczak-Madej, Grażyna Kamińska-Winciorek, et al.
Journal of Cancer Research and Clinical Oncology|November 28, 2024
Comparing epidemiological and clinical data from RPS patients documented in a German cancer registry to a cohort from TARPSWG reference centresFranziska Neemann, Lina Jansen, Silke Hermann, et al.
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2025
Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspectsSilvia Hofer, Chantal Pauli, Beata Bode, et al.
Nature Medicine|October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Future Oncology (London, England)|December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanomaJason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Nature Medicine|January 4, 2024
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Pageof 50

Showing results (341-350 of 491) with videos related to

Sort By:
Pageof 50
International Journal of Molecular Sciences|February 27, 2026
Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in ChondrosarcomaAgnieszka E Zając, Piotr Rutkowski, Anna Szumera-Ciećkiewicz, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 2020
Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohortNikki S IJzerman, Mahmoud Mohammadi, Dimitri Tzanis, et al.
Annals of Surgery|January 5, 2016
Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working GroupAlessandro Gronchi, Dirk C Strauss, Rosalba Miceli, et al.
Immunotherapy|December 23, 2020
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in PolandBożena Cybulska-Stopa, Renata Pacholczak-Madej, Grażyna Kamińska-Winciorek, et al.
Journal of Cancer Research and Clinical Oncology|November 28, 2024
Comparing epidemiological and clinical data from RPS patients documented in a German cancer registry to a cohort from TARPSWG reference centresFranziska Neemann, Lina Jansen, Silke Hermann, et al.
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2025
Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspectsSilvia Hofer, Chantal Pauli, Beata Bode, et al.
Nature Medicine|October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Future Oncology (London, England)|December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanomaJason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Nature Medicine|January 4, 2024
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Pageof 50